Under the agreement, USPI will fund a new plasma-based cancer (PBC) therapy programme for USMI's development of biomedical applications for plasma technology, particularly in the treatment of cancer.
The newly-funded programme will expand the collaboration between Jerome Canady, M.D. Chief Science Officer of the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), chairman of the board of managers at USPI and Dr. Michael Keidar, the A. James Clark Professor of Engineering in GW's Department of Mechanical and Aerospace Engineering.
Canady, Keidar, consulting scientists and other subsidiaries of USPI will explore potential applications for cold atmospheric plasma (CAP) in the treatment of cancer.
Plasma medicine is a new and rapidly-emerging field of research with the use of plasma in cancer treatment being one of the most promising applications.
To date, the remarkable anti-cancer capacity of CAP has been demonstrated using dozens of cancer cell lines, both in vitro and in vivo.
The effect of CAP on numerous types of cancer including brain cancer, skin cancer, breast cancer, colorectal cancer, lung cancer, cervical cancer, leukemia, head and neck cancer, and hepatoma have been intensively investigated.
The use of CAP-based instruments has already shown promise in the treatment of cancer.
In January 2017, Rush University Medical surgical team led by Dr. Keith Millikan successfully used the Canady Helios Cold Plasma Scalpel (CHCPS) to selectively kill cancerous tissue during a two-stage liver resection for advanced inoperable liver cancer.
The innovative technology allowed the surgical removal of the cancerous tissue without damaging the blood supply to the remaining liver.
JCRI-ABTS and USMI will apply for FDA Investigational Device Exemption to start a clinical trial on the Canady HeliosTM Cold Plasma Device for the treatment of cancer in 4Q17
US Medical Innovations, LLC (USMI) is a private US biomedical device company and wholly-owned subsidiary of US Patent Innovations, LLC, a private investment company.
USMI's focus is developing advanced innovative affordable plasma and robotic electrosurgical devices and striving to develop innovative devices in the field of plasma technology for the eradication of cancer.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial